AUGUST 4, 2020
Biophytis Receives Approval from Brazilian Health Regulatory Agency to Start COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure. Read the Press Release
JULY 27, 2020
Biophytis Receives Approval from the French Health Authority (ANSM) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release
JULY 3, 2020
Biophytis announces a € 6.1 million capital increase through private placement. Read the Press Release
JULY 1st, 2020
Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release
JULY 1st, 2020
Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release
June 23, 2020
Biophytis successfully completes a € 4 million capital increase to strengthen its financial structure. Read the Press Release
June 11, 2020
Biophytis Receives MHRA Approval to Initiate the COVA Clinical Trial in the UK with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release
June 10, 2020
Biophytis announces the issue of 2,050,000 new shares in a capital increase reserved for NEGMA. Read the Press Release
MAY 28, 2020
Results of the Combined General Meeting of May 28, 2020: All ordinary and extraordinary resolutions have been adopted. Read the Press Release
MAY 20, 2020
Biophytis second AGM to take place on May 28, 2020 without the physical presence of its shareholders. Read the Press Release